Our in vitro experiments on glioma cells showed that bevacizumab not only increased the expression level of IRF1, but also increased the size of IRF1 (Figure 2A and 3A), suggesting a possible posttranslational modification by bevacizumab treatment. This evidence concerns the gene IRF1 and central nervous system cancer.